ABOUT VENTURA

KNOW-HOW

Kurt and Andreas are serial entrepreneurs with many years of experience in the biotech and pharmaceutical industry. With our expert knowledge, we help shape the long-term development of our portfolio companies and provide them with access to a broad investor and business network. By doing so, we support exceptional entrepreneurs in their quest to accelerate medical breakthrough.

CAPITAL

Ventura Biomed Investors typically invests EUR 1 – 5 million per company, always in consortia with other funds and within Europe. To increase our impact and reach, we can furthermore invest via our investment platform Ventura Ace, which comprises selected, renowned private investors. For both Ventura Biomed Investors and Ventura Ace, our investment focus is on early-stage life science companies developing pioneering technologies and innovative therapies.

LEADERSHIP

Dr. Andreas Jenne

Dr. Andreas Jenne

Andreas has launched several biotech companies, which he managed in leading positions. Among others, he was CEO of Kinaxo, a proteomics service provider that was acquired by Evotec, and NEO New Oncology, a cancer diagnostics company that was bought by Siemens Healthcare.

In addition to his investment activities, he is an active board member in various biotech and medtech companies. Andreas holds a Ph.D. in Chemistry from the Ludwig-Maximilians- University in Munich.

Dr. Kurt Schwarz

Dr. Kurt Rudolf Schwarz

Kurt is an active investor and business angel. Besides investing in all major asset classes, he is engaged in numerous health care companies. Furthermore, he is an active member in a variety of cultural, philanthropic and political institutions.

Kurt was member of the supervisory board of Schwarz Pharma, where he represented the Schwarz family as a major shareholder. Other professional affiliations include Merck & Co. as well as Harvard Medical School and Massachusetts General Hospital where he worked as a scientist and physician.

PORTFOLIO

KUPANDO

KUPANDO is developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases

KUPANDO
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. Kupando aims to deliver safe and affordable treatment for solid tumors and
...
NEOSPHERE

NEOsphere Biotechnologies supports the development of small molecule degraders within strategic partnerships

NEOsphere Biotechnologies
is a pioneering proteomics company that creates value in strategic partnerships looking to systematically discover and develop therapeutic degrader targets that cannot be accessed by traditional small molecule approaches. Located in Munich’s biotech hub, the company uses cutting-edge mass spectrometry technology to screen libraries of tens of thousands of compounds against proteomes of more than 10,000 proteins. Purpose-built data processing systematically extracts high-probability candidates that are validated as novel degrader targets via mechanistic methods like ubiquitination analysis at an
...
IRUBIS

IRUBIS offers analytical instruments based on midinfrared spectroscopy as a new standard in real-time bioprocess monitoring

IRUBIS
IRUBIS GmbH, a Munich-based biotech company, has developed Monipa to bring biological drugs faster to the market. This process analytical technology improves process development and manufacturing of biopharmaceuticals. Monipa is a mid-infrared spectrometer system that enables real-time monitoring and control of important parameters in bioprocessing. It’s single-use interface and the simplifying cal ibration model, revolutionizes the bioprocess industry. Monipa is already in use by key opinion leaders in the biopharma industry.
Read post
ABALOS

Abalos develops a novel virus-based anti-cancer therapy that triggers immune cells to attack primary tumors and metastases

ABALOS
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’spower specifically against cancer cells. Through viral replication within cancer cells, Abalos’arenavirus-based drug candidates are designed to awake precise innate and adaptive immuneresponses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.
Read post
NAVIGNOSTICS

Navignostics provides spatial single-cell proteomic analysis of tumor samples to enable personalized therapies for cancer patients

NAVIGNOSTICS
Navignostics is a spin-off company from the University of Zurich, which is leveraging spatial single-cell proteomics to perform advanced analyses of tumor samples. As a start–up active in the personalized medicine field, Navignostics strives to provide innovative solutions to identify the best possible treatment for each cancer patient. In addition, Navignostics provides advanced services to pharmaceutical companies to accelerate cancer drug development and to contribute to companion diagnostic development.
Read post
NIA HEALTH

NIA health markets a clinical diagnosis and therapy software for patients suffering from chronic skin conditions

NIA HEALTH
Nia Health is a spin-off of the Charité Universitätsmedizin Berlin. The start-up develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. With its platform, Nia Health addresses an often highly underserved patient population and generates treatment-relevant real-world evidence. With its innovative machine vision approach, Nia Health enables accurate documentation of disease and therapy progression and thus optimized treatment. The company works closely with German patient associations and leading clinicians. The digital medical solutions
...
IQURE PHARMA

iQure Pharma Inc. is a CNS-focussed biotech company dedicated to the development of new epilepsy and pain management therapeutics

IQURE PHARMA
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure’s leading compound, iQ-007, is a neuromodulator targeting toxic levels of glutamate in the synaptic cleft. An elevated level of glutamate leads to neurotoxicity and ultimately to neural degeneration. iQ-007 operates by a Positive Allosteric Modulation of Excitatory Amino Acid Transporter 2 (EAAT2 PAM), which is responsible for up to 90% of glutamate uptake. A decrease in EAAT2 function is
...
PHINE BIO

PHiNE enables a wide range of healthcare applications employing its proprietary gene transfer technology

PHINE BIO
PHiNE Bio is a biopharmaceutical start-up company based in Basel, Switzerland. The company has developed highly efficient and cost-effective technologies for precise gene transfer both ex vivo and in vivo. Its proprietary gene transfer platform, build on protein engineering and artificial intelligence, addresses previously unsolved challenges in cell and gene therapy.
...

TEAM INVESTMENTS

RSP SYSTEMS

RSP Systems is developing a non-invasive monitoring device for diabetics that measures blood glucose levels fast and reliably without finger pricking

RSP SYSTEMS
RSP Systems is dedicated to improving the health and quality of life of people worldwide through its unique and patented solution for non-invasive glucose monitoring. The first targeted application is a product line of non-invasive glucose monitors, which provides people with diabetes with a convenient, pain-free alternative to the current invasive solutions. RSP combines Critical-Depth Raman spectroscopy with advanced mathematical modelling to accurately measure glucose in the interstitial fluid. The Company has demonstrated its technology in numerous clinical studies
...
SCI RHOM

SciRhom has developed first-in-class therapeutic antibodies against iRhom2, a key regulator of inflammatory processes, aiming to improve the treatment of autoimmune diseases

SCI RHOM
SciRhom GmbH, based in Martinsried, Germany, is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research conducted at the Hospital for Special Surgery (HSS) and a well-established network of industry experts, SciRhom has profound experience in antibody development. The company has developed first-in-class anti-iRhom2 antibodies, which will enter clinical trials in 2024. Four comprehensive
...
QANATPHARMA

Qanatpharma is a Canadian-Swiss clinical-stage biopharmaceutical company developing novel therapies for cardiovasular disease

QANATPHARMA
Qanatpharma’s drug development program streams focus on cerebral arteries that autoregulate brain perfusion and on skeletal muscle resistance arteries that govern total peripheral resistance, a key regulator of blood pressure. Research and clinical trials are carried out in close collaboration with the Toronto Centre for Microvascular Medicine (TCMM), embedded in a world-class innovation hub in the downtown Toronto university-hospital corridor.
TQ THERAPEUTICS

TQx has developed a highly automated and ultra-fast process for bedside cell therapy that makes these innovative treatments accessible to patients and affordable for healthcare systems

TQ THERAPEUTICS
TQ Therepeutics platform will transform the traditional way of producing cellular therapies, which is often slow, expensive, and hard to scale, into a very fast and highly automated process right at the bedside. The TQx process creates genetically modified immune cells (like CAR-T cells) and deliver cell therapy directly to the patient. This avoids the complicated and costly steps of centralized production. As a result, this approach unlocks the full potential of autologous cell therapies for treating conditions that were
...
ARCORIS BIO

arcoris bio transforms biomedical research and diagnostics with innovative technologies and reagents

ARCORIS BIO
arcoris bio, based in Schlieren, Switzerland, develops next-generation technologies for the detection of biomarkers in research and diagnostics. The company's DNA-based biomarker detection platform, MUSE, offers universal, programmable signal amplification that enables multiplex assays with unprecedented sensitivity. By facilitating the measurement of multiple hard-to-detect biomarkers in a single sample at high throughput, MUSE is poised to set new standards in digital pathology and molecular diagnostics.
PREOMICS

PreOmics is a supplier of reagents and equipment for mass spectrometry-based proteomics, setting new standards for protein analysis

PREOMICS
PreOmics empowers its clients in life sciences to establish biological knowledge through efficient, reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy, and commitment empower us to be both creative and quality focused – A trusted partner with deeply rooted scientific experience. We envisage a future with revolutionary proteomic discovery processes open for everyone. Tools that reveal hidden causes of diseases, ensure sustainable nutrition and provide diagnoses that enhance lives and society.
Read post
OPTIMED

Optimed is engaged in research, development, manufacturing and worldwide distribution of high-quality medical products for minimal invasive therapy

OPTIMED
Optimed, based in Ettlingen/Germany, is engaged in research, development, manufacturing and worldwide distribution of high-quality medical products for minimal invasive therapy since 1996. A total of more than 200 employees in the headquarters, production and international sales guarantee that the company organization runs smoothly. Our „German Heart“ mentality pays off – not only in terms of the special quality of our products, also in terms of our consistently reliable supply chain.

NEWS

Kupando Announces First Patient Dosed in Phase 1 Clinical Study of Lead Candidate KUP101 in Advanced Solid Tumors

•	Milestone marks Kupando’s evolution from a research-focused organization to a clinical-stage biopharmaceutical company
•	Phase 1 trial evaluates KUP101, a differentiated dual Toll-Like Receptor (TLR) 4/7 agonist designed to harness innate immunity and induce trained immunity
•	Unlike conventional therapies targeting specific mutations, KUP101 operates as a tissueagnostic treatment with proven preclinical synergy alongside checkpoint inhibitors

SCHÖNEFELD, Germany, 6 August 2026 – Kupando, a pioneering biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity and induces trained
immunity for use...

iQure Pharma Awarded Grant from The Michael J. Fox Foundation to Advance EAAT2 Program in Parkinson’s Disease

June, 2026 – Princeton, NJ – iQure Pharma, a clinical-stage biotech company developing first-in-class astrocyte-targeted therapies designed to restore glutamate balance in CNS disorders, today announced it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further investigate the role of EAAT2 modulation with iQ-007 in Parkinson’s disease.

Read more: iQure Pharma Awarded Grant from The Michael J. Fox Foundation to Advance...

Kupando Secures Additional €10 Million in Series A Financing to
Advance Novel Immuno-Oncology and Infectious Diseases Programs

•	Kupando raised an additional €10 million in Series A financing, bringing the total Series A funding to €23 million.
•	Investment again led by Remiges Ventures, co-led by LifeCare Partners, with participation from all existing investors and new investor Carma Fund.
•	Proceeds will be used to fund the Phase 1b clinical study of KUP101 in advanced solid tumors and to accelerate preclinical programs in infectious diseases.
•	KUP101 is a differentiated dual TLR 4 and 7 agonist, harnessing innate immune stimulation and trained innate immunity.

Schönefeld, Germany, 18 March 2026 – Kupando, a pioneering...

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
Initiative Focused on Scaling Advanced Cell and Gene Therapy to Enhance Patient Access

LAKE ZURICH, Ill., January 14, 2026 – Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing.

Read more: Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology

•	Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors.
•	MUSE®, arcoris bio’s nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity.
•	The funding will accelerate industrialization of the MUSE® platform, expansion of strategic partnerships, and launch of new products.

Schlieren, Switzerland, 6. November 2025 – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, has secured CHF 6.3 million...

Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025

-- Combination with bispecific T-cell engagers amplifies T-cell recruitment and cytotoxic activity against tumor cells --

Düsseldorf, Germany, November 4, 2025 – Abalos Therapeutics announced today that it will present new preclinical data on the development of ABX-001 and its potential to further intensify anti-tumoral effects when combined with bispecific T-cell engagers, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Professor Karl S. Lang, PhD, Chair of Immunology at the Medical Faculty, University Duisburg-Essen and Scientific Founder of Abalos, will present the...

Read more: Abalos Therapeutics to Present Preclinical Data Highlighting Potent,...

ABOUT VENTURA

KNOW-HOW

CAPITAL

LEADERSHIP

PORTFOLIO

TEAM INVESTMENTS

NEWS

Kupando Announces First Patient Dosed in Phase 1 Clinical Study of Lead Candidate KUP101 in Advanced Solid Tumors

iQure Pharma Awarded Grant from The Michael J. Fox Foundation to Advance EAAT2 Program in Parkinson’s Disease

Kupando Secures Additional €10 Million in Series A Financing toAdvance Novel Immuno-Oncology and Infectious Diseases Programs

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology AgreementInitiative Focused on Scaling Advanced Cell and Gene Therapy to Enhance Patient Access

arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology

Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025

Kupando Secures Additional €10 Million in Series A Financing to
Advance Novel Immuno-Oncology and Infectious Diseases Programs

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
Initiative Focused on Scaling Advanced Cell and Gene Therapy to Enhance Patient Access